分期 来自妙佑医疗国际员工 医护团队根据诊断检测和医疗程序检查结果确定您的癌症分期。分期可让医护团队了解您的癌症严重程度以及肝脏的功能状况。 肝细胞癌分期有不同的系统。有些使用数字,有些使用字母。巴塞罗那临床肝癌分期系统是一种常用的系统。该系统分为五个分期。它用数字 0 表示癌症的最早期,用字母 A 到 D 表示其他分期。 使用此分期系统,肝细胞癌的分期如下: 0 期,也被称为极早期。 0 期肝细胞癌是指肝脏中有一个小于 2 厘米(略大于 3/4 英寸)的癌细胞生长物,被称为肿瘤。肿瘤尚未扩散到血管或肝脏以外。 A 期,也被称为早期。 A 期肝细胞癌是指肝脏中有一个大于 2 厘米(略大于 3/4 英寸)的肿瘤。或者它可能意味着有多达三个肿瘤,每个肿瘤都小于 3 厘米(略大于 1 英寸)。肿瘤尚未扩散到血管或肝脏以外。 B 期,也被称为中期。 B 期肝细胞癌意味着肿瘤比 A 期多,而且可能更大。肿瘤可能累及肝脏的不同部位。肿瘤尚未扩散到血管或肝脏以外。 C 期,也被称为晚期。 C 期肝细胞癌意味着肿瘤已经生长到累及血管,或者癌细胞已经扩散到肝脏以外。癌症从原发部位扩散出去时,被称为转移性癌症。 D 期,也被称为终末期。 D 期肝细胞癌意味着肝脏健康状况不佳,无法接受治疗。这是因为肝硬化非常严重。医护团队可能会专注于舒适护理,而不是试图治愈癌症。 申请预约 诊断与治疗生存率 Dec. 31, 2025 Share on: FacebookTwitterWeChatWeChatCloseWeibo 显示参考文献 Elsevier Point of Care. Clinical Overview: Hepatocellular carcinoma. https://www.clinicalkey.com. Accessed Nov. 18, 2024. Hepatocellular carcinoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514. Accessed July 25, 2025. Primary liver cancer treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq. Accessed Nov. 18, 2024. Liver (hepatocellular) cancer prevention (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq. Accessed Nov. 18, 2024. Schwartz JM, et al. Clinical features and diagnosis of hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed July 30, 2025. Abdalla EK, et al. Overview of treatment approaches for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 5, 2025. Stuart KE. Systemic treatment for advanced hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024. Schwartz JM, et al. Epidemiology and risk factors for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024. Curley SA, et al. Surgical resection of hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024. Tsoulfas G, et al. Liver transplantation for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 5, 2025. Palliative care. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454. Accessed Nov. 18, 2024. Hepatitis C prevention and control. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis-c/prevention/index.html. Accessed Nov. 18, 2024. 2020-2025 Dietary Guidelines for Americans. U.S. Department of Health and Human Services and U.S. Department of Agriculture. https://www.dietaryguidelines.gov. Accessed Nov. 18, 2024. TACE. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/chemoembol. Accessed Nov. 18, 2024. Radioembolization (Y90). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/radioembol. Accessed Nov. 18, 2024. Thermal ablation for tumor treatment. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/thermal-ablation-therapy. Accessed Nov. 18, 2024. Liver cancer. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/liver-cancer/about/index.html. Accessed Nov. 18, 2024. Hepatitis B vaccine. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis-b/vaccination/index.html. Accessed Feb. 7, 2025. Feldman M, et al., eds. Hepatic tumors and cysts. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 11th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed July 25, 2025. DeVita VT Jr, et al., eds. Cancer of the liver. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. ProQuest Ebook Central. Wolters Kluwer; 2023. Accessed Feb. 11, 2025. Suriawinata A. Pathology of malignant liver tumors. https://www.uptodate.com/contents/search. Accessed July 25, 2025. Kalman RS, et al. Epidemiology, clinical manifestations, diagnosis and treatment of fibrolamellar carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 6, 2025. Ferri FF. Jaundice in the adult patient. In: Ferri's Clinical Advisor 2026. Elsevier; 2026. https://www.clinicalkey.com. Accessed Aug. 1, 2025. McPherson RA, et al., eds. Evaluation of liver function. In: Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 1, 2025. Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology. 2022; doi:10.1016/j.jhep.2021.11.018. Cancer stat facts: Liver and intrahepatic bile duct cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/livibd.html. Accessed Aug. 5, 2025. Tecentriq (prescribing information). Genentech; 2024. https://www.tecentriq.com. Accessed Aug. 5, 2025. Lenvima (prescribing information). Eisai; 2025. https://www.lenvima.com. Accessed Aug. 5, 2025. Health Education & Content Services. Liver cancer: Hepatocellular carcinoma. Mayo Clinic; 2023. Nimmagadda R. Allscripts EPSi. Mayo Clinic. Feb. 26, 2025. Liver SPOREs. National Cancer Institute. https://dctd.cancer.gov/research/spores/focus-area/liver. Accessed Aug. 6, 2025. Santol J, et al. An APRI+ALBI-based multivariable model as preoperative predictor for posthepatectomy liver failure. Annals of Surgery. 2023; doi:10.1097/SLA.0000000000006127. Starlinger P, et al. Combined APRI/ALBI score to predict mortality after hepatic resection. BJS Open. 2021; doi:10.1093/bjsopen/zraa043. Kern AE, et al. MicroRNA based prediction of posthepatectomy liver failure and mortality outperforms established markers of preoperative risk assessment. Annals of Surgical Oncology. 2025; doi:10.1245/s10434-025-17528-x. Dong Y, et al. Preoperative von Willebrand factor is an independent predictive biomarker for posthepatectomy liver failure — A multivariable model with APRI+ALBI. Liver Transplantation. 2025; doi:10.1097/LVT.0000000000000676. 相关 相关医疗程序 CT 扫描 丙氨酸氨基转移酶(ALT)血液检测 冷冻消融术治疗癌症 化疗 天冬氨酸氨基转移酶(AST)血液检测 姑息疗法 放射疗法 正电子发射断层扫描 癌症射频消融治疗 癌症治疗 癌症生物疗法 碱性磷酸酶(ALP)血液检测 磁共振成像 肝功能检测 肝脏活检 肝脏移植 胆红素检测 血浆凝血酶原时间测定 超声波检查 针刺活检 显示更多相关医疗程序 Mayo Clinic 新闻 Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial 产品与服务 书籍:《妙佑医疗国际家庭健康手册》 简报:妙佑医疗国际卫生来信 — 数字版 显示更多来自妙佑医疗国际的产品和服务 肝细胞癌(HCC)症状与病因诊断与治疗分期生存率医生与科室在 Mayo Clinic 治疗 CON-20202301 疾病与状况 肝细胞癌(HCC)